Skip to main content

Menstrual hormone-induced cyclic thumb CMC instability and degeneration in women: a systematic review



Relaxin is a hormone which peaks during the luteal phase of the menstrual cycle, and a known collagenolytic promoter that has been shown to avidly bind tissues supporting the trapeziometacarpal (TMC) joint in women. We hypothesize a causal linkage between cyclic binding of relaxin to the supporting tissues of the female TMC joint; and to the earlier onset of more severe TMC osteoarthritis (OA) commonly seen in women.


A systematic literature review was performed per PRISMA guidelines, qualitatively and quantitatively assessing papers regarding relaxin–TMC joint stability interactions. The primary outcome variable was TMC joint degeneration/loss of function; the “late stage” consequences of relaxin-induced instability. The secondary outcome variable was presence of early signs of relaxin-induced instability; specifically asymptomatic TMC joint laxity in young women.


In healthy young women, menstrual cycle relaxin peaks corresponded with asymptomatic TMC joint instability. Immunohistochemical studies of TMC arthroplasty patients showed avidly increased relaxin binding to supporting tissues around the TMC joint in women but not men. Demographic analysis of patients from the TMC arthroplasty studies show a predominantly female cohort, who were on average significantly younger than the male surgical patients.


Each relaxin peak during the menstrual cycle can target receptors on the soft tissues supporting the TMC joint, including—critically—the main stabilizing ligament: the anterior oblique. The cyclic instability is typically asymptomatic for years after menarche, but causes cumulative chondral microtrauma. This likely causes the early-onset, high severity TMC joint OA clinically pervasive among female patients at orthopedic hand clinics. Further research is indicated to develop risk assessment strategies and potential interventional options before and after the onset of hormonal laxity-induced OA.


  • It is widely recognized among hand surgeons that female patients present at a younger age for basal thumb osteoarthritis, with more severe degeneration.

  • The little-known menstrual hormone relaxin, which peaks every ovulatory cycle, may be responsible for the female predominance of this pathology.

  • The soft tissue support structures for the thumb are known to express relaxin receptors which, when activated, trigger lysis of collagen and other extracellular matrix components.

  • Laxity in soft tissues supporting the thumb, such as the deep anterior oblique ligament, would result in joint instability and microtrauma.

  • If women cyclically experience thumb instability and cumulative cartilage microtrauma from menarche through menopause, the female propensity to develop TMC arthritis is aptly justified.


The unparalleled functional capacity of the thumb is facilitated by the unique structure of trapeziometacarpal (TMC) joint; a structure which increases the risk of OA development [1]. The TMC saddle joint has minimal intrinsic osseous stability, instead relying on attached ligaments for support, particularly the deep anterior oblique (palmar beak) ligament [1, 2]. The extensive number of relaxin binding sites around the female TMC joint incrementally decrease stability during child-bearing years [3,4,5].; post-menopausal women comprise 80% of the TMC joint OA patient population (Fig. 1) [6].

Fig. 1
figure 1

Legend, consequential pathology from long-term and/or repetitive TMC instability: The first site of pathology (1), the trapeziometacarpal (TMC) joint, will eventually sublux in the radial direction, causing chondral cartilage damage and creating a second site of pathology at the thumb metacarpophalangeal (MCP) joint. As the first phalanx is hyperextended in an attempt to compensate for the metacarpal subluxation relative to the carpal bone, the cartilage of the MCP joint becomes damaged (2). As a result, patients begin to notice marked weakness in the thumb, particularly with pinching and grasping tasks (3)

Female reproductive hormone relaxin, noted for facilitating parturition, is infrequently discussed outside of obstetrics. In non-pregnant women, relaxin peaks during the luteal phase of the menstrual cycle, and it is critical to note that in women the hormone triggers collagen degradation (Fig. 2). The heavily reinforced pubic symphysis exemplifies this; in non-pregnant women, approximately 2600 pounds of force are required to separate the joint [7]. During pregnancy, relaxin facilitates joint separation via extensive collagen degradation [7]. Accordingly, it is concerning that women have receptors for this powerful hormone beyond the reproductive tract (Fig. 3) [3, 5, 8].

Fig. 2
figure 2

Legend, menstrual cycle hormone peaks and molecular effects: The sequence of hormone peaks for ovulatory menstrual cycles. Estrogen levels peak first, increasing expression of relaxin receptors in the body and increasing global synthesis of MMPs. The drop in estrogen triggers ovulation, and the remains of that ovarian follicle form the corpus luteum. As a temporary endocrine body, the corpus luteum secretes progesterone to prepare the endometrium for pregnancy and to sustain itself. It also synthesizes and releases relaxin, which binds receptors to activate MMPs recently upregulated by estrogen while also suppressing transcription of de novo collagen. Relaxin is active during the luteal phase, chiefly CD21-24

Fig. 3
figure 3

Legend, approximated cumulative lifetime instability: On average in the US, women reach menarche (start having ovulatory menstrual cycles) at age 14, and enter menopause (cease having ovulatory menstrual cycles) at age 49. Individual ages can vary widely. The luteal phase when relaxin peaks, CD21 to CD24, is consistent among women. With an average of 13 menstrual cycles per year and 4 days of instability per cycle, over 35 years of menstrual activity, women are subject to roughly 5 years of TMC joint instability before reaching age 50

Known female-specific locations of relaxin family peptide receptors (RXFPs)—the anterior cruciate ligament (ACL), TMC joint tissues—portend common female pathophysiology, such as ACL tears and basilar thumb OA (Fig. 4) [3,4,5]. Despite TMC joint osteoarthritis (OA) being degenerative and ACL ruptures being acute, both show the harms of relaxin activity in periarticular tissues [3,4,5]. TMC joint OA can severely impact completion of activities of daily living, and quality of life. The present review aims to assess literature on relaxin and TMC joint OA, to evaluate female OA risk and prevalence, elucidate the hormonal aspects of OA development, and identify any potential preventive (pre-osteoarthritic) or interventional (after the onset of arthritis) options for management.

Fig. 4
figure 4

Legend, structual factors of the TMC joint detrimentally impacted by relaxin: The structures which compose the TMC joint or provide supplemental stability which contain relaxin receptors and may be degenerated in settings of elevated relaxin. Right: Dorsal view of the right hand. Relaxin attenuates the dorsoradial ligament, allowing lateral translation of the first metacarpal relative to the trapezium. Left: palmar view of the right hand. Relaxin attenuates the volar oblique ligament critical for TMC joint stability, allowing abnormal medial, lateral, and anterior (palmar) translation of the first metacarpal relative to the trapezium. Both: Trapezium chondrocytes contain relaxin receptors, resulting in direct cartilage damage in addition to damage caused by abnormal movement patterns


Literature Search

This literature search was refined from a prior Joanna Briggs Institute (JBI) protocol-compliant scoping review search for a separate manuscript, with broad parameters including any English-language literature discussing both relaxin and any musculoskeletal pathology and/or injury. It was noted during this earlier review that a significant number of results addressed relaxin and the trapeziometacarpal joint in women, leading to the present, focused systematic review.

The initial scoping review search strategies were developed by the authors and an orthopedic health sciences librarian with expertise in literature reviews in June 2020, with a repeat search for new literature relevant to the present review performed by the authors in December 2021. The initial search strategy was developed for MEDLINE. The first search string cast a wide net for any musculoskeletal injuries/pathology, with MeSH terms such as “hip injury” and “musculoskeletal injury”. Accompanying text words and phrases included “ligament” and “cartilage”. The second search string focused on female variations in relaxin hormone levels and activity, with MeSH terms such as “relaxin” and “relaxin receptor”. Accompanying text words and phrases included “cyclic hormonal variation” and “eumenorrheic”. The full search strategy for MEDLINE was as follows:

((((((((((((((((((hip[MeSH Terms])) OR (hip joint[MeSH Terms])) OR (hip injury[MeSH Terms])) OR (hip dysplasia[MeSH Terms])) OR (femoroacetabular impingement[MeSH Terms])) OR (non-arthritic hip pain[Text Word])) OR (hip dysplasia[Text Word])) OR (femoroacetabular impingement[Text Word])) OR (cam lesion[Text Word])) OR (pincer lesion[Text Word])) OR (acetabular labral tear[Text Word])) OR (musculoskeletal injury[MeSH Terms])) OR (musculoskeletal injury[Text Word])) OR (ligament[Text Word])) OR (ligament[MeSH Terms])) OR (cartilage[MeSH Terms])) OR (cartilage[Text Word]))


(((((((((((relaxin[MeSH Terms]) OR (relaxin receptor[MeSH Terms])) OR (N(alpha) formyltyrosyl relaxin[MeSH Terms])) OR (hormone releasing intrauterine device[MeSH Terms])) OR (contraceptive agents[MeSH Terms])) OR (cycle, menstrual[MeSH Terms])) OR (dysmenorrhea[MeSH Terms])) OR (oligomenorrhea[MeSH Terms])) OR (amenorrhea[MeSH Terms])) OR (cyclic hormonal variation[Text Word])) OR (hormonal variation[Text Word]))

The search strategy was then adapted for EMBASE and CINAHL. Full search strategies for these databases are available upon request. The reference list of all included sources of evidence was screened for additional source materials via SCOPUS. All identified citations were uploaded to EndNote (EndNote X9.2, Clarivate Analytics, PA, USA) and duplicates removed by a combination of software screening and manual review. Titles and abstracts were then screened by two authors independently against the inclusion criteria, with animal-only studies being excluded. A full-text assessment was then performed to identify final inclusions.

Our initial scoping review screen yielded 82 included studies [8]. During the process of data extraction and analysis for the hip injury/relaxin scoping review, the authors noted a number of quality research studies addressing relaxin and TMC joint laxity/osteoarthritis in women. This information was condensed and presented in the scoping review as supporting evidence, and thus was not explored as a topic of focus. The authors decided to perform a more stringent systematic review screen of the 82 scoping review papers, selecting for papers specifically addressing the relaxin–TMC relationship, and excluding any lower quality literature, such as case studies. This “re-screen” was again performed independently by two junior authors, with oversight from the senior authors, in accordance with PRISMA guidelines.

Statistical Analyses

Excel v.1808 (Microsoft Inc, Redmond, WA) was utilized to perform basic demographic calculations and all Student’s t tests. Student’s t tests were used to evaluate demographic data among all patients, specifically mean percent of female patients and mean patient age. They were also utilized for assessment of study outcome variables if data was present in sufficient amounts for an appropriately powered analysis.

Outcome Variables

This group of studies facilitated a multi-outcome assessment of the impact of elevated relaxin on the female TMC joint. Our primary outcome was TMC joint degeneration and loss of function, evaluated via patients being indicated for/undergoing arthroplasty and/or radiographic evidence of osteoarthritis; and functional assessments, such as patient-reported outcome scores (PROs) or findings on physical exam in the clinic. Needing arthroplasty and/or severe degeneration on imaging was considered the “late stage” of detrimental relaxin effects.

Our secondary outcome, early symptoms of relaxin effects, evaluated the extent and impact of relaxin-induced TMC joint laxity in younger women and/or women with no significant osteoarthritis of the joint. The extent of relaxin-induced laxity had to be measured by an objective observer in a clinical/research setting, looking at passive and active range of motion, ability to resist applied stress, etc. The impact of the relaxin-induced laxity could be determined via PROs, subject failure during research tests of strength/stability, or changes in physical task metrics during periods of peak vs. trough relaxin levels (i.e., significant changes in grip strength).

Other outcome variables assessed are important considerations in current relaxin research: further elucidating the extent to which serum relaxin concentration (SRC) reflects ongoing relaxin activity, given its preference for paracrine signaling; and the extent to which the physiological location and concentration of relaxin receptors indicates a location of relaxin activity, particularly when comparing males vs. females. Evaluating the first point, paracrine vs. endocrine activity of relaxin at various serum levels, was best assessed in women with documented detectable SRC measurements, known relaxin receptors around the TMC joint, and documentation of TMC joint health. The second point, evaluating the location of relaxin receptors versus locations of known relaxin activity in women and men, was well-suited for examination in the present review Unlike the ACL, it is known that men have relaxin receptors present on TMC-adjacent tissue, yet do not experience early and/or severe osteoarthritis at rates similar to women.

Currently, the impact of relaxin has been well-documented from micro- to macro-level studies of ACL tears. The spectrum of evidence from molecular ACL degradation due to relaxin-activated MMPs, to population-level correlation of high relaxin levels and ACL tears, has constructed a sturdy base for future ACL/relaxin research. Therefore, with this review we aimed to determine what evidence is present or absent for TMC degeneration vs. relaxin levels; to see if pathways from relaxin peaks to injury or pathological state could be firmly established. We also assessed any proposed relaxin-focused interventions aiming to prevent injury/joint degeneration.

Study Quality

Study quality was evaluated by two authors independently, prior to reaching consensus scores on the Modified Coleman Criteria Scale (MCMS). Oversight was provided by the senior authors. As a group, the six included studies had an average MCMS of 21.6 ± 12.2 (range: 28 to 58); ranking poor quality per MCMS categories. However, two of the immunohistochemistry-focused studies were notable outliers [3, 4], with MCMS scores at least 14 points lower than the remaining four studies which contained clinical information. With the two outlying studies removed, the average MCMS was 50.3 ± 6.8 (range 44 to 58); ranking fair quality per MCMS categories.


Of the 82 studies which met the criteria for inclusion in the authors' prior scoping review [8], six studies met criteria for inclusion in the systematic review of relaxin vs. TMC joint pathology [3, 4, 9,10,11,12]. All six studies assessed the location/properties of relaxin receptors around the TMC joint [4, 11, 12], and/or the pathophysiologic effects of relaxin on the TMC joint both early in life (joint instability) and later in life (joint osteoarthritis) [3, 9,10,11,12]. Except for the case–control study by Em et al. [9], all included studies were prospective cohort designs [3, 4, 10,11,12]. Three studies focused on TMC arthroplasty patients [3, 4, 11], two focused on benign joint hypermobility syndrome (BJHS) [9, 12], while the final study assessed hormonal contraceptive (HCP) use (Table 1) [10].

Table 1 Properties of Included Studies

The 504 total included subjects were distributed unevenly among the studies, with a range of 8–289 and an average of 84 ± 105 subjects. The two largest studies, with 377 collective subjects, were assessing BJHS, while the three arthroplasty studies totaled 72 subjects (Table 1). In concordance with the preferential sex-specific manifestation of both BJHS and TMC OA, and as a result of artificial subject sex restriction by researchers, the average percent of female subjects per study was 80.2% ± 22.2%. Accordingly, as women tend to display symptoms of both conditions at a younger age, the average patient age was 44.0 ± 19.4 years (Table 1).


The present review aims to assess current literature regarding relaxin and TMC joint OA to better quantify the risk of pathophysiology among women, to determine a plausible mechanistic route for hormone related TMC OA development, and to pinpoint any promising strategies discussed for preventive or interventional purposes.

Relaxin Overview

Analytical discussion of joint-specific relaxin effects requires adequate global knowledge of the hormone; its endocrine properties, receptor behavior, and general homeostatic/physiologic roles. Relaxin (RLX) is a peptide hormone present in both sexes, with preferentially paracrine activity. In women, the corpus luteum synthesizes most but not all relaxin, and prostatic tissue synthesizes relaxin in men [13,14,15]. Average serum relaxin concentration (SRC) between sexes is similar when women are not experiencing luteal phase peaks, but with relaxin often acting locally, SRC does not consistently reflect the extent of hormone activity (Appendix: Table 3) [15, 16].

Accordingly, the location of relaxin family peptide receptors (RXFPs) is a sensitive indicator of relaxin’s physiological roles. From a sex-specific musculoskeletal consideration, RXFPs are uniformly present on certain articular/peri-articular sites only in women, and RXFP expression is primed by estrogen and progesterone [14, 17,18,19]. Relaxin modulates ECM turnover, upregulating MMP-1/-13 (collagenases) and MMP-2/-9 (gelatinases) to degrade existing collagen while suppressing synthesis of new collagen via downregulation of transcription [14, 17,18,19]. Female relaxin levels peak in a temporal relationship with estrogen and progesterone menstrual cycle peaks (Fig. 2) [14, 20].

TMC OA Risk, Prevalence, and Severity per Sex

The first aim of this review was to assess the prevalence and risk of TMC OA development in women vs. men. Two of the three TMC arthroplasty studies were mixed sex, not restricted by researchers (Clifton et al. [3]. and Wolf et al. [11]). Data from these 64 patients readily affirmed the sex-specific predominance of TMC OA, with the average percent of female vs. male patients being 64.0% ± 4.2% vs. 36.0% ± 4.2% (p < 0.05). Only Clifton et al. (n = 15) [3]. provided average age per sex, and despite the small number of patients, nearly reached significance when evaluating if women undergo surgical intervention at an earlier age compared to men (age 59.0 ± 7.8 years vs. 67.0 ± 5.8 years, p = 0.06).

Interestingly, all-subject analyses by Clifton et al. [3]. showed no correlation between extent of relaxin receptor staining and sex; and a lack of significant difference in receptor concentration between men and women. Similarly, the Eaton–Littler score of TMC OA severity was not significantly associated with sex. However, their analysis showed clinically relevant significance after first sex-stratifying patients, and then evaluating the male and female patient group Eaton scores vs. extent of relaxin receptor staining. While the male group did not show significant results, the female group had a strongly positive correlation between Eaton score and amount of relaxin receptors.

This supports prior hypotheses that men have protective factors (lower circulating SRC, androgen-associated cartilage protection) preventing laxity as the joint’s binding capacity for relaxin increases [3]. Patients with severe disease, requiring trapeziectomy, were all female in this study; significantly younger at time of surgery compared to the standard male patient, with the need for trapeziectomy having strong positive correlations with Eaton score and RXFP1 concentration (Table 2) [3]. Wolf et al. [11] did not sex-stratify their results, although patients were majority female (61%) (Table 1). In this study, increased SRC was significantly, positively correlated with expression of RXFP1 and MMP-1 (collagenase) in TMC joint peri-articular tissues (Table 2).

Table 2 Qualitative Review of Study Results

The Hormonal Aspect of Trapeziometacarpal Joint Osteoarthritis Development

The pathophysiology of osteoarthritis development can be a complex, multifactorial route. In the present review, the studies of younger, hypermobile women without TMC joint pathology were valuable for understanding early patterns of instability. Markers of early-onset TMC joint OA could potentially be discerned from such research, be it physical exam measures or laboratory/radiographic testing results [9, 12]. In addition, studies of women exposed to exogenous hormonal influences such as OCPs (Pokorny et al. [10]) allow hormone fluctuations to be viewed as a modifiable variable. Finally, clarifying the molecular-level mechanisms of OA development was facilitated by three studies analyzing tissues extracted during TMC arthroplasty (Table 2) [3, 4, 11].

In examining hormone-associated TMC joint OA development in women, it was found that the risk of CMC joint subluxation had a significant positive correlation with detectable SRC in young, healthy women [12]. High serum relaxin was also found to significantly correlate with increased expression of relaxin receptors and the powerful relaxin-activated collagenase, MMP-1, in the anterior oblique ligament of the CMC joint; one of the joint’s major structural stabilizers [11]. This correlation of serum relaxin, relaxin receptors, and MMP-1 concentration was detected in tissue samples from female TMC arthroplasty patients [11].

Therefore, a reasonable hypothetical pathway for the development of hormone-associated TMC joint OA in women begins with elevated serum relaxin levels. High SRC increases TMC joint subluxation risk at a young age, with subluxations having the potential to acutely damage chondral cartilage and worsen ligament laxity. As high SRC levels persist, the supporting tissues of the TMC joint express more receptors, binding more relaxin, which activates the increased number of local collagenases. Collagen degradation of the soft tissues supporting the TMC joint would further worsen joint laxity, allowing for increased subluxations and abnormal weight loading detrimental to chondral cartilage health (Fig. 1).

Potential Preventive and/or Interventional Options to Mitigate Hormone-Related TMC Damage

Relaxin is necessary for correct function of the female reproductive tract, with undesirable extraneous effects beyond the reproductive organs, indicating that targeted, rather than systemic, treatments may be most promising [3]. It should be noted that hormonal contraceptives have been shown to reduce high relaxin levels and even decrease the rate of ACL tears among certain demographic groups, such as teen girls [21, 22]. However, only one study by Pokorny et al. [10] assessed impact of OCPs on laxity of the hand (second and fifth digits), and found no significant effects. Relaxin effects on women who are and are not using OCPs, in joints with well-established relaxin-mediated changes, such as the TMC joint, should be investigated.

The issue then becomes determining methods to locally decrease relaxin levels or counteract the pathophysiologic effects of relaxin peaks. Sustainability of the methods is a requirement, given that a woman reaching menarche and menopause at average ages, with average length menstrual cycles, will experience approximately 1800 days, or nearly 5 years, of lifetime luteal phase days during which her TMC joints could be at risk (Fig. 3).

While OCP use may not be desirable for some women, a low-cost but labor-intensive option for management is menstrual cycle tracking. The increased joint laxity occurs over a set span of days (cycle day 21 to cycle day 24) on average [23,24,25]. Therefore, higher risk days can be identified by tracking menstrual cycles via calendar or any number of free phone, computer, and tablet applications [24, 25]. This is likely most useful for women who are already showing signs of TMC pathology. They can consult with occupational therapists regarding activity restrictions, supportive bracing, or other practices to adopt during this phase of the menstrual cycle. Intervening at the point of mild pathology would ideally prevent or slow the progressive development of subsequent damage (Fig. 1) [11, 25].

As relaxin receptors have synovial localization, the TMC joint synovial tissue is a target for focused treatment in the future [26,27,28,29]. In contrast to the female reproductive hormones, androgens such as testosterone actually have a collagen-protective effect which almost directly opposes the mechanism of collagenolysis triggered by relaxin [30, 31]. As testosterone already has local application mechanisms (topical cream, implanted subdermal pellets), consideration of a directly-applied androgen treatment during peak relaxin days for women with moderate-to-severe TMC pathology is worth consideration.

Perspectives and Significance

Common medical knowledge about relaxin is almost entirely limited to an obstetrical context, as is medical research about hormonal activity. It is critical to recognize that (1) Relaxin is physiologically active in women throughout a large span of their life, whether pregnant or not; and (2) Effects of relaxin are not limited to the reproductive organs in women; it is a powerful peptide hormone which modulates extracellular matrix turnover in numerous tissues throughout the body. A paradigm shift in medical care for women is necessary, to account for this significant physiological factor [8]. Early research should focus on discerning the tissues in which relaxin acts beyond the reproductive system; as the present review shows, a closer examination of female-predominant pathophysiology may yield answers here.


This was a systematic review of small sample size studies pertaining to the TMC joint and relaxin, increasing the risk of bias. Furthermore, the studies assessed both relaxin (serum concentration levels vs. immunohistochemical staining of local receptors), and TMC joint degradation (radiographic evidence of OA vs. surgical evidence of OA) via different measures, some likely to be more valid and reliable than the others.


Each relaxin peak during the menstrual cycle can target receptors on the soft tissues supporting the TMC joint, including—critically—the main stabilizing ligament: the anterior oblique. The cyclic instability is typically asymptomatic for years after menarche, but causes cumulative chondral microtrauma. This likely causes the early-onset, high severity TMC joint OA clinically pervasive among female patients at orthopedic hand clinics. Further research is indicated to develop risk assessment strategies and potential interventional options before and after the onset of hormonal laxity-induced OA.

Availability of data and materials

The data sets used and/or analysed during the current study are available from the corresponding author on reasonable request.


  1. Sung JK, Akelman E. Thumb carpometacarpal arthritis. Tech Orthop. 2009;24(1):23–6.

    Article  Google Scholar 

  2. Clifton K, Rodner CM, Drissi H, Wolf JM. Detection of relaxin receptor in the synovium and dorsoradial ligament of the trapeziometacarpal joint: Not a clinical study. J Hand Surg. 2012;37(8):7.

    Article  Google Scholar 

  3. Clifton KB, Rodner C, Wolf JM. Detection of relaxin receptor in the dorsoradial ligament, synovium, and articular cartilage of the trapeziometacarpal joint. J Orthop Res. 2014;32(8):1061–7.

    Article  CAS  Google Scholar 

  4. Lubahn J, Ivance D, Konieczko E, Cooney T. Immunohistochemical detection of relaxin binding to the volar oblique ligament. J Hand Surg Am. 2006;31(1):80–4.

    Article  Google Scholar 

  5. Dragoo JL, Lee RS, Benhaim P, Finerman GA, Hame SL. Relaxin receptors in the human female anterior cruciate ligament. Am J Sports Med. 2003;31(4):577–84.

    Article  Google Scholar 

  6. Haase SC, Chung KC. An evidence-based approach to treating thumb carpometacarpal joint arthritis. Plast Reconstr Surg. 2011;127(2):918–25.

    Article  CAS  Google Scholar 

  7. Owens K, Pearson A, Mason G. Pubic symphysis separation. Fetal Maternal Med Rev. 2002;13(2):141–55.

    Article  Google Scholar 

  8. Parker EA, Meyer AM, Goetz JE, Willey MC, Westermann RW. Do relaxin levels impact hip injury incidence in women? A scoping review. Front Endocrinol. 2022;13.

  9. Em S, Oktayoglu P, Bozkurt M, et al. Serum relaxin levels in benign hypermobility syndrome. J Back Musculoskelet Rehabil. 2015;28(3):473–9.

    Article  Google Scholar 

  10. Pokorny MJ, Smith TD, Calus SA, Dennison EA. Self-reported oral contraceptive use and peripheral joint laxity. J Orthop Sports Phys Ther. 2000;30(11):683–92.

    Article  CAS  Google Scholar 

  11. Wolf J, Scott F, Etchell E, Williams AE, Delaronde S, King KB. Serum relaxin is correlated with relaxin receptors and MMP-1 in the anterior oblique ligament. Osteoarthritis Cartilage. 2012;20:S250.

    Article  Google Scholar 

  12. Wolf JM, Williams AE, Delaronde S, Leger R, Clifton KB, King KB. Relationship of serum relaxin to generalized and trapezial-metacarpal joint laxity. J Hand Surg Am. 2013;38(4):721–8.

    Article  Google Scholar 

  13. MacLennan AH. The role of relaxin in human reproduction. Clin Reprod Fertil. 1983;2(2):77–95.

    CAS  PubMed  Google Scholar 

  14. Powell BS, Dhaher YY, Szleifer IG. Review of the multiscale effects of female sex hormones on matrix metalloproteinase-mediated collagen degradation. Crit Rev Biomed Eng. 2015;43(5–6):401–28.

    Article  Google Scholar 

  15. Wolf JM, Cameron KL, Clifton KB, Owens BD. Serum relaxin levels in young athletic men are comparable with those in women. Orthopedics. 2013;36(2):128–31.

    Article  Google Scholar 

  16. O’Byrne EM, Tabachnick M, Anderson LL, Steinetz BG. Characterization of the circulating form of porcine relaxin: biological activity and terminal amino acids. Endocrinology. 1989;124(6):2920–7.

    Article  CAS  Google Scholar 

  17. Kapila S, Park Y, Ahmad N, Hosomichi J, Hayami T, Tacon C. Mechanisms for Relaxin’s modulation of MMPs and matrix loss in fibrocartilages. Ital J Anat Embryol. 2013;118(1 SUPPL):62–5.

    PubMed  Google Scholar 

  18. Kapila S, Xie Y. Targeted induction of collagenase and stromelysin by relaxin in unprimed and β-estradiol-primed diarthrodial joint fibrocartilaginous cells but not in synoviocytes. Lab Invest. 1998;78(8):925–38.

    CAS  PubMed  Google Scholar 

  19. Weiss M, Nagelschmidt M, Struck H. Relaxin and collagen metabolism. Horm Metab Res. 1979;11(6):408–10.

    Article  CAS  Google Scholar 

  20. Goldsmith LT, Weiss G, Steinetz BG. Relaxin and its role in pregnancy. Endocrinol Metab Clin North Am. 1995;24(1):171–86.

    Article  CAS  Google Scholar 

  21. Nose-Ogura S, Yoshino O, Yamada-Nomoto K, et al. Oral contraceptive therapy reduces serum relaxin-2 in elite female athletes. J Obstet Gynaecol Res. 2017;43(3):530–5.

    Article  CAS  Google Scholar 

  22. Samuelson K, Balk EM, Sevetson EL, Fleming BC. Limited evidence suggests a protective association between oral contraceptive pill use and anterior cruciate ligament injuries in females: a systematic review. Sports Health. 2017;9(6):498–510.

    Article  Google Scholar 

  23. Anderson T, Shultz SJ, Kincaid Z, et al. Capturing detectable relaxin concentrations in eumenorrheic non-pregnant women. Women Sport Phys Activ J. 2019;27(1):30–6.

    Article  Google Scholar 

  24. Bryant-Greenwood GD, Greenwood FC. The physiology of relaxin. Proc Endocr Soc Aust. 1979;22:1.

    Google Scholar 

  25. Bryant-Greenwood GD, Mercado-Simmen R, Yamamoto SY, Arakaki RF, Uchima FD, Greenwood FC. Relaxin receptors and a study of the physiological roles of relaxin. Adv Exp Med Biol. 1982;143:289–314.

    Article  CAS  Google Scholar 

  26. Alvesde Oliveira J, Marques Simek V, Gon Ãalves TS, Soares Reis Vilanova L, Maria Bovi Ambrosano G, Rodrigues Garcia RCM. Female hormones fluctuation and chewing movement of patients with disc displacement. Revista Odonto Ciencia. 2012;27(1):20–5.

    Article  Google Scholar 

  27. Arnold C, Van Bell C, Rogers V, et al. The relationship between serum relaxin and knee joint laxity in female athletes. Orthopedics. 2002;25(6):669–73.

    Article  Google Scholar 

  28. Bonaventure J, de La Tour B, Tsagris L, Eddie LW, Tregear G, Corvol MT. Effect of relaxin on the phenotype of collagens synthesized by cultured rabbit chondrocytes. Biochim Biophys Acta. 1988;972(2):209–20.

    Article  CAS  Google Scholar 

  29. Brophy RH, Silvers HJ, Mandelbaum BR. Anterior cruciate ligament injuries: Etiology and prevention. Sports Med Arthrosc Rev. 2010;18(1):2–11.

    Article  Google Scholar 

  30. Freeman BM, Mountain DJ, Brock TC, et al. Low testosterone elevates interleukin family cytokines in a rodent model: a possible mechanism for the potentiation of vascular disease in androgen-deficient males. J Surg Res. 2014;190(1):319–27.

    Article  CAS  Google Scholar 

  31. Henmi H, Endo T, Nagasawa K, et al. Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. Biol Reprod. 2001;64(1):157–62.

    Article  CAS  Google Scholar 

  32. Grossman J, Frishman WH. Relaxin: a new approach for the treatment of acute congestive heart failure. Cardiol Rev. 2010;18(6):305–12.

    Article  Google Scholar 

  33. Kleine SA, Budsberg SC. Synovial membrane receptors as therapeutic targets: A review of receptor localization, structure, and function. J Orthop Res. 2017;35(8):1589–605.

    Article  Google Scholar 

  34. Ando H, Moriwaki C. Studies on relaxin assay with x-ray photography. Endocr J. 1960;7:167–70.

    Article  CAS  Google Scholar 

  35. Galey S, Konieczko EM, Arnold CA, Cooney TE. Immunohistological detection of relaxin binding to anterior cruciate ligaments. Orthopedics. 2003;26(12):1201–4.

    Article  Google Scholar 

Download references


The authors would like to thank Jennifer Deberg at the Hardin Library for Health Sciences for her assistance with literature searches.


Not applicable.

Author information

Authors and Affiliations



EAP, IGF, and JABV conceptualized the review focus. EAP and AMM performed literature database searches, screened literature for inclusion, and extracted data from the included literature under the supervision and guidance of JABV and IGF. EAP and AMM analyzed the extracted data. EAP was a major contributor in writing the manuscript, with JABV, IGF, and AMM completing substantial constructive reviews and editorial suggestions. All authors read and approved the final manuscript.

Authors' information

JABV is a Hand and Upper Extremity Division surgeon within the Department of Orthopedics and Rehabilitation. IGF is a research associate within this division.

Corresponding author

Correspondence to Emily A. Parker.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



See Table 3.

Table 3 Cellular/molecular effects of relaxin-relevant literature findings

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Parker, E.A., Meyer, A.M., Garcia Fleury, I. et al. Menstrual hormone-induced cyclic thumb CMC instability and degeneration in women: a systematic review. Biol Sex Differ 13, 32 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: